Teaching hospital

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Tuesday, April 2, 2024
Hospital, TMX Group, Teaching hospital, Phase, OTCQB, Liver

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaşa, Sütçü İmam University Hospital in the city of Kahramanmaraş, and the Gazi University Hospital in Ankara, the capital of Turkey.
  • The trial now has a total of seven clinical sites across Turkey and Canada.

EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
AAGL, Patient, TMS, Investment, Endometriosis, Therapy, USD, Marketing, Congress, Urology, Teaching hospital, INPI, Food, Prostate cancer, EAU, Cancer, Hospital, Intellectual property, AUA, FDA, Diagnosis, DIE, Growth, EDAP, Operating cost, EDT, Randomized controlled trial

Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.

Key Points: 
  • Total revenue in the HIFU business for the fourth quarter of 2023 was EUR 7.5 million (USD 8.1 million), as compared to EUR 5.4 million (USD 5.5 million) for the fourth quarter of 2022.
  • The increase was driven by 10 Focal One systems sold in the fourth quarter of 2023 versus 7 systems sold in the fourth quarter of 2022.
  • Total revenue in the Distribution business for the fourth quarter of 2023 was EUR 9.9 million (USD 10.7 million), as compared to EUR 6.7 million (USD 7.0 million) for the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was EUR 3.5 million (USD 3.8 million), compared to an operating loss of EUR 1.6 million (USD 1.6 million) in the fourth quarter of 2022.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

University Hospital of Southampton NHS Foundation Trust

Retrieved on: 
Tuesday, April 9, 2024
SARS, Teaching hospital

A reprimand is being issued to University Hospital of Southampton NHS Foundation Trust as they have only responded to 59% of incoming SARs within the statutory timeframe during the period of 01 August 2022 to 01 July 2023.

Key Points: 

A reprimand is being issued to University Hospital of Southampton NHS Foundation Trust as they have only responded to 59% of incoming SARs within the statutory timeframe during the period of 01 August 2022 to 01 July 2023.
University Hospital of Southampton NHS Foundation Trust

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Retrieved on: 
Tuesday, March 12, 2024
Principal, GP2, Faculty, Breast cancer, Gregorio, Immunotherapy, Disease, Patient, Knowledge, GM-CSF, Research, Hospital, Observation, Pi, Cancer, Death, Teaching hospital, Baylor College of Medicine, ECIS, Complutense University of Madrid, Woman, Prognosis, Book, Vaccine, Map

The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.

Key Points: 
  • The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.
  • These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week.
  • Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.
  • Breast cancer is the leading cause of death in women between the ages 35-45 in Spain with 6,836 deaths in 2022.

HD Nursing Recognizes National Patient Safety Awareness Week, Celebrates Notable Achievements in Fall and Pressure Injury Prevention

Retrieved on: 
Monday, March 11, 2024
Professional Services, Nursing, Health, Data Analytics, Hospitals, Managed Care, RN, CVP, Culture, CSSBB, CCRN, Pressure, Face, Home, Communication, OE, Patient, CNS, DNP, APRN, Doctor of Philosophy, Teaching hospital, Mercy Hospital, MSN, BSN, Clinical nurse specialist, Heart, Hospital, Patient safety, Safety, HD, ICU, FAAN, OCN, CQA, ONC

In observance of National Patient Safety Awareness Week (March 10-16, 2024), HD Nursing , the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention, is pleased to highlight its recent positive benchmarks, underscoring the top-down commitment to advancing patient safety.

Key Points: 
  • In observance of National Patient Safety Awareness Week (March 10-16, 2024), HD Nursing , the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention, is pleased to highlight its recent positive benchmarks, underscoring the top-down commitment to advancing patient safety.
  • Celebrating Fall Prevention at UT Southwestern: In 2018, William P. Clements Jr. University Hospital and Zale Lipshy Pavilion both implemented the HD Nursing Fall Prevention Program.
  • “These positive benchmarks underscore the effectiveness of our Falls Prevention Program and the unwavering commitment of healthcare providers to prioritize patient safety.
  • As we mark National Patient Safety Awareness Week, these achievements inspire us to continue pioneering innovative solutions that make a meaningful impact on healthcare outcomes."

Mishe and SUNY Downstate Health Sciences University Partner to Offer Real Transparent Pricing for Comprehensive Healthcare Services

Retrieved on: 
Thursday, March 28, 2024
CFO, Partnership, Patient, Insurance, Downstate, Teaching hospital, SUNY Downstate Medical Center, Physician, Fear

BROOKLYN, N.Y., March 28, 2024 /PRNewswire/ -- Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its comprehensive suite of inpatient and outpatient healthcare services.

Key Points: 
  • BROOKLYN, N.Y., March 28, 2024 /PRNewswire/ -- Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its comprehensive suite of inpatient and outpatient healthcare services.
  • "Our solutions empower providers and payers to compliantly offer transparent prices so patients can confidently access care.
  • We're thrilled to partner with University Hospital at Downstate and University Physicians of Brooklyn to become the source of truth for real pricing across the care continuum."
  • "This historic partnership is a turning point for the healthcare industry," said Sean Smith, CFO of University Hospital at Downstate.